Avalyn Pharma Inc. quarterly report, Q2 FY2026

Avalyn Pharma Inc. 10-Q Summary: Q2 2026

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company developing inhaled medicines for rare respiratory diseases, specifically progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF). The company completed its Initial Public Offering (IPO) on May 1, 2026, converting all outstanding preferred stock to common stock. As of June 30, 2026, the company had 44,333,095 shares of voting common stock outstanding.

Key Financial Metrics

Metric Q2 2026 (3 Months) Q2 2025 (3 Months) YTD 2026 (6 Months) YTD 2025 (6 Months)
Revenue $0 $0 $0 $0
Net Loss $(28.9) million $(20.2) million $(55.8) million $(37.7) million
Operating Expenses $31.3 million $21.8 million $59.2 million $40.5 million
Cash & Cash Equivalents $264.2 million (as of June 30, 2026)
Marketable Securities
Total Liquidity $413.5 million (Cash + Marketable Securities)
Debt (Term Loan) $15.0 million principal outstanding (Net carrying value: $14.8 million)
Accumulated Deficit $(321.2) million

Material Changes vs. Prior Period

  • Capital Structure Transformation: The company completed its IPO in May 2026, raising approximately $316.6 million in net proceeds. All series of redeemable convertible preferred stock were converted to common stock, eliminating the preferred stock equity class.
  • Liquidity Surge: Cash and cash equivalents increased from $52.3 million at December 31, 2025, to $264.2 million at June 30, 2026. Total liquidity (including marketable securities) stands at $413.5 million.
  • Expense Growth: Operating expenses increased significantly due to the advancement of clinical trials.
    • R&D Expenses: Increased to $24.7 million for Q2 2026 from $17.9 million in Q2 2025. This was driven by the progression of the Phase 2b MIST trial (AP01) and Phase 2 AURA trial (AP02).
    • G&A Expenses: Increased to $6.6 million for Q2 2026 from $3.9 million in Q2 2025, reflecting increased headcount and costs associated with public company operations.
  • Debt Financing: In February 2026, the company entered a $30.0 million term loan facility with Banc of California and drew down $15.0 million.

Guidance, Outlook, and Risks

  • Cash Runway: Management believes current cash, cash equivalents, and marketable securities ($413.5 million) are sufficient to fund operations into 2029.
  • Clinical Milestones:
    • AP01 (Inhaled Pirfenidone): Phase 2b MIST trial is ongoing; topline data anticipated in the second half of 2027.
    • AP02 (Inhaled Nintedanib): Phase 2 AURA trial is ongoing; topline data anticipated in late 2027.
    • AP03 (Combination): Phase 1 study expected to initiate by the end of 2026.
  • Key Risks:
    • Dependence on Lead Candidates: Business success relies heavily on AP01 and AP02. Failure in clinical trials or regulatory approval would materially harm the company.
    • Regulatory Uncertainty: Novel inhaled formulations face complex regulatory pathways. The FDA previously requested additional device compatibility studies for AP02.
    • Third-Party Reliance: The company relies on PARI Pharma for nebulizer technology and third-party CROs/CDMOs for manufacturing and trials.
    • Profitability: The company has incurred significant losses since inception and expects to continue doing so for the foreseeable future.

Investor Verification Checklist

  • Verify the enrollment status and timeline for the MIST (AP01) and AURA (AP02) clinical trials, as delays could impact the 2027 data readout.
  • Confirm the terms of the PARI License Agreement, specifically regarding milestone payments and royalty obligations upon commercialization.
  • Monitor the Term Loan covenants with Banc of California to ensure no restrictions on future capital raising or operations are triggered.
  • Assess the impact of the reverse stock split (1-for-19.2417) on share liquidity and trading volume post-IPO.
  • Review the stock-based compensation expense trajectory, which increased significantly in Q2 2026 due to new equity plans adopted for the IPO.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.